Induction of a type I interferon signature in normal human monocytes by gadolinium-based contrast agents: Comparison of linear and macrocyclic agents

Clinical and Experimental Immunology

Volumn 175, Issue 1, 2014, Pages 113-125

  Wermuth, P J ^a   Jimenez, S A ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Gadolinium based contrast agent; Macrophages; Nephrogenic systemic fibrosis; Tissue fibrosis; Type I interferon

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; COLLAGEN TYPE 1; COLLAGEN TYPE 3; FIBRONECTIN; GADODIAMIDE; INTERFERON; INTERLEUKIN 13; INTERLEUKIN 4; MACROCYCLIC COMPOUND; TRANSFORMING GROWTH FACTOR BETA; VASCULOTROPIN;

ARTICLE; EXPOSURE; FIBROBLAST; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IN VITRO STUDY; INFLAMMATION; MONOCYTE; MONOCYTE CULTURE; NEPHROGENIC SYSTEMIC FIBROSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SUPERNATANT; T LYMPHOCYTE ACTIVATION;

GADOLINIUM-BASED CONTRAST AGENT; MACROPHAGES; NEPHROGENIC SYSTEMIC FIBROSIS; TISSUE FIBROSIS; TYPE I INTERFERON;

ACTINS; COLLAGEN TYPE I; COLLAGEN TYPE III; CONTRAST MEDIA; DERMIS; FEMALE; FIBROBLASTS; FIBRONECTINS; GADOLINIUM; GENE EXPRESSION REGULATION; HUMANS; INTERFERON TYPE I; MACROCYCLIC COMPOUNDS; MALE; MONOCYTES; NEPHROGENIC FIBROSING DERMOPATHY;

EID: 84888881917     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/cei.12211     Document Type: Article

References (41)

1. Cowper SE, Robin HS, Steinberg SM, Su LD, Gupta S, LeBoit PE. Scleromyxoedema-like cutaneous diseases in renal-dialysis patients. Lancet 2001; 356:1000-1001.
2. Cowper SE, Su LD, Bhawan J, Robin HS, LeBoit PE. Nephrogenic fibrosing dermopathy. Am J Dermatopathol 2001; 23:383-393.
3. Jimenez SA, Artlett CM, Sandorfi N etal. Dialysis-associated systemic fibrosis (nephrogenic fibrosing dermopathy). Arthritis Rheum 2004; 50:2660-2666.
4. Mendoza FA, Artlett CM, Sandorfi N, Latinis K, Piera-Velazquez S, Jimenez SA. Description of twelve cases of nephrogenic fibrosing dermopathy and review of the literature. Semin Arthritis Rheum 2006; 35:238-249.
5. Grobner T. Gadolinium - a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant 2006; 21:1745.
6. Prince MR, Zhang H, Morris M etal. Incidence of nephrogenic systemic fibrosis at two large medical centers. Radiology 2008; 248:807-816.
7. Altun E, Martin DR, Wertman R, Lugo-Somolinos A, Fuller ER III, Semelka RC. Nephrogenic systemic fibrosis: change in incidence following a switch in gadolinium agents and adoption of a gadolinium policy - report from two U.S. universities. Radiology 2009; 253:689-696.
8. Kendrick-Jones JC, Voss DM, De Zoysa JR. Nephrogenic systemic fibrosis, in patients with end-stage renal disease on dialysis, in the greater Auckland region, from 2000-2006. Nephrology (Carlton) 2011; 16:243-248.
9. High WA, Ayers RA, Chandler J, Zito G, Cowper SE. Gadolinium is detectable within the tissue of patients with nephrogenic systemic fibrosis. J Am Acad Dermatol 2007; 56:21-26.
10. Boyd AS, Zic JA, Abraham JL. Gadolinium deposition in nephrogenic fibrosing dermopathy. J Am Acad Dermatol 2007; 56:27-30.
11. Kay J, Bazari H, Avery LL, Koreishi AF. Case records of the Massachusetts General Hospital. Case 6-2008. A 46-year-old woman with renal failure and stiffness of the joints and skin. N Engl J Med 2008; 358:827-838.
12. Cacheris WP, Quay SC, Rocklage SM. The relationship between thermodynamics and the toxicity of gadolinium complexes. Magn Reson Imaging 1990; 8:476-481.
13. Idee JM, Port M, Raynal I, Schaefer M, Le Greneur S, Corot C. Clinical and biological consequences of transmetallation induced by contrast agents for magnetic resonance imaging: a review. Fundam Clin Pharmacol 2006; 20:563-576.
14. Kuo PH. Gadolinium-containing MRI contrast agents: important variations on a theme for NSF. J Am Coll Radiol 2008; 5:29-35.
15. Morcos SK. Extracellular gadolinium contrast agents: differences in stability. Eur J Radiol 2008; 66:175-179.
16. Newton BB, Jimenez SA. Mechanism of NSF: new evidence challenging the prevailing theory. J Magn Reson Imaging 2010; 30:1277-1283.
17. Wermuth PJ, Del Galdo F, Jimenez SA. Induction of the expression of profibrotic cytokines and growth factors in normal human peripheral blood monocytes by gadolinium contrast agents. Arthritis Rheum 2009; 60:1508-1518.
18. Del Galdo F, Wermuth PJ, Addya S, Fortina P, Jimenez SA. NFκB activation and stimulation of chemokine production in normal human macrophages by the gadolinium-based magnetic resonance contrast agent Omniscan: possible role in the pathogenesis of nephrogenic systemic fibrosis. Ann Rheum Dis 2010; 69:2024-2033.
19. Wermuth PJ, Jimenez SA. Gadolinium compounds signaling through TLR4 and TLR7 in normal human macrophages: establishment of a proinflammatory phenotype and implications for the pathogenesis of nephrogenic systemic fibrosis. J Immunol 2012; 189:318-327.
20. Edward M, Quinn JA, Burden AD, Newton BB, Jardine AG. Effect of different classes of gadolinium-based contrast agents on control and nephrogenic systemic fibrosis-derived fibroblast proliferation. Radiology 2010; 256:735-743.
21. Varani J, DaSilva M, Warner RL etal. Effects of gadolinium-based magnetic resonance imaging contrast agents on human skin in organ culture and human skin fibroblasts. Invest Radiol 2009; 44:74-91.
22. Perone PA, Weber SL, DaSilva M etal. Collagenolytic activity is suppressed in organ-cultured human skin exposed to a gadolinium-based MRI contrast agent. Invest Radiol 2010; 45:42-48.
23. Edward M, Quinn JA, Mukherjee S etal. Gadodiamide contrast agent 'activates' fibroblasts: a possible cause of nephrogenic systemic fibrosis. J Pathol 2008; 4:584-593.
24. Cheng Y, Maozi L, Rongchang L, Wang C, Bai C, Wang K. Gadolinium induces domain and pore formation of human erythrocyte membrane: an atomic force microscopic study. Biochim Biophys Acta 1999; 1421:249-260.
25. Davies JQ, Gordon S. Isolation and culture of human macrophages. Methods Mol Biol 2005; 290:105-116.
26. Idee JM, Port M, Medina C etal. Possible involvement of gadolinium chelates in the mechanism of nephrogenic systemic fibrosis: an update. Radiol Clin North Am 2009; 47:855-869.
27. Port M, Idee JM, Medina C, Robic C, Sabatou M, Corot C. Efficiency, thermodynamic and kinetic stability of marketed gadolinium chelates and their possible clinical consequences: a critical review. Biometals 2008; 21:469-490.
28. Chakrabarti R, Chakrabarti R. Novel role of extracellular carbon dioxide in lymphocyte proliferation in culture. J Cell Biochem 2001; 83:200-203.
29. Darzynkiewicz Z, Jacobson B. HEPES-buffered media in lymphocyte cultures. Proc Soc Exp Biol Med 1971; 136:387-393.
30. Lu M, Lin SC, Huang Y etal. XIAP induces NF-kappaB activation via the BIR1/TAB1 interaction and BIR1 dimerization. Mol Cell 2007; 26:689-702.
31. Pitha PM. Innate antiviral response: role in HIV-1 infection. Viruses 2011; 3:1179-1203.
32. Fu Y, Xie C, Yan M, Joh JW, Lu C, Mohan C. The lipopolysaccharide-triggered mesangial transcriptome: evaluating the role of interferon regulatory factor-1. Kidney Int 2005; 67:1350-1361.
33. Wang J, Basagoudanavar SH, Wang X etal. NF-κB RelA subunit is crucial for early IFN-beta expression and resistance to RNA virus replication. J Immunol 2010; 185:1720-1729.
34. Wang WL, Liu W, Gong HY, Lin CC, Wu JL. Activation of cytokine expression occurs through the TNFα/NF-κB-mediated pathway in birnavirus-infected cells. Fish Shellfish Immunol 2011; 31:10-21.
35. Higgs BW, Liu Z, White B etal. Patients with systemic lupus erythematosus, myositis, rheumatoid arthritis and scleroderma share activation of a common type I interferon pathway. Arthritis Rheum 2011; 70:2029-2036.
36. Liu S, Mayes MD, Tan FK etal. Correlation of interferon-inducible chemokine plasma levels with disease severity in systemic sclerosis. Arthritis Rheum 2013; 65:226-235.
37. Tao J, Li L, Tan Z etal. Up-regulation of CC chemokine ligand 20 and its receptor CCR6 in the lesional skin of early systemic sclerosis. Eur J Dermatol 2011; 21:731-736.
38. Degrandi D, Hoffmann R, Beuter-Gunia C, Pfeffer K. The proinflammatory cytokine-induced IRG1 protein associates with mitochondria. J Interferon Cytokine Res 2009; 29:55-67.
39. McDermott JE, Vartanian KB, Mitchell H, Stevens SL, Sanfillippo A, Stenzel-Poore MP. Identification and validation of Ifit1 as an important innate immune bottleneck. PLOS ONE 2012; 7:e:36465.
40. Fineschi S, Goffin L, Rezzonico R etal. Antifibroblast antibodies in systemic sclerosis induce fibroblasts to produce profibrotic chemokines, with partial exploitation of Toll-like receptor 4. Arthritis Rheum 2008; 58:3913-3923.
41. Meldrum KK, Zhang H, Hile KL, Moldower LL, Dong Z, Meldrumd DR. Profibrotic effect of interleukin-18 in HK-2 cells is dependent on stimulation of the Toll-like receptor 4 (TLR4) promoter and increased TLR4 expression. J Biol Chem 2012; 287:40391-40399.